【摘要】 本文报告用CHOP方案治疗103例非何杰金氏淋巴瘤的经验。全部病例均经病理组织学证实,按工作分型属中、高度恶性者71％。除标准CHOP或CHOP—Bleo方案外,26例化疗后曾用局部放疗。化疗均在三疗程上,66％用药6疗程以上。 治疗结果:全组总缓解率90.7％,完全缓解率57.7％。74例初治病例总缓解率95.6％,完全缓解率60.3％。全组中位生存期(MST)22.5个月,获CR者MST36个月以上,未获CR者MST不足12个月。全组1年生存率66.7％,3年生存率36.4％。获CR者3年生存率约59％。主要毒副反应为消化道反应、白细胞降低及脱发,但多不严重,无致死性毒副反应发生。部份病例有心电图改变,但无心力衰竭发生。更多还原

【Abstract】 103 cases of NHL,all histologically proved, were treated with CHOP orCHOP-Bleo chemotherapy. 71% of the cases were median-grade or high grade lymphoma according to the working formulation, in 26 cases adjuvant radiotherapy were also applied to the bulky disease area following chemotherapy.Results For the whole group, total response rate was 90.7% and CR rate was 57.7%. For 74 previously untreated cases, total response rate was 95,6% and CR 60.3%. MST of the whole group was 22. 5m.,. for patients achieved CR the MST was > 36m (not yet reached) and only < 12m. for the induction failures. 3 year survival of the whole group was 36.4% and was 59% for the CR patients. Side effects including leucopenia, alopecia and EKG changes were reversible, and no fatal toxicity was encountered.更多还原